Replies to post #196879 on Biotech Values

[DewDiligence]

(MRK/BIIB)—Samsung Bioepis reports detailed phase-3 results for Humira, Enbrel, and Remicae FoBs:

http://www.biosimilarnews.com/positive-phase-iii-outcomes-from-samsung-bioepis-biosimilar-candidates

Hitting the primary endpoint in the Enbrel and Remicade trials was reported in Jun 2015 (#msg-114478003).